According to Forbes, Indian billionaire cardiac surgeon Devi Shetty’s Narayana Health has agreed to acquire Practice Plus Group Hospitals for £189 million ($248 million), marking its first entry into the U.K. market. The Bangalore-based company will acquire all 60,001 shares at £3,146 apiece through its unit Narayana Hrudayalaya U.K. Practice Plus Group is the fourth-largest provider for the U.K.’s National Health Service, with NHS patients accounting for 93% of its £229 million revenue in the year ended September 2024, operating 10 hospitals and surgical centers with 330 beds and 2,500 employees. Narayana Health, which operates 18 hospitals across India with over 5,200 beds, projects the deal will make it among India’s top three healthcare providers by revenue. This strategic acquisition represents a fascinating test case for global healthcare delivery models.
Sponsored content — provided for informational and promotional purposes.
The Volume-Driven Healthcare Model Goes Global
What makes this acquisition particularly significant is the collision of two fundamentally different healthcare philosophies. Narayana Health built its reputation on what I’ve observed as the “Walmart-ization” of complex medical procedures—high volumes, standardized protocols, and radical cost efficiency that made cardiac surgery accessible to India’s middle class. Practice Plus Group, meanwhile, operates within the constraints of the NHS system, where budget pressures and waiting lists have created a crisis in elective care. The real test will be whether Narayana can apply its volume-driven, process-optimized approach to a system where 93% of revenue comes from public funding. This isn’t just another cross-border acquisition; it’s a laboratory experiment in whether emerging market healthcare innovations can solve developed market healthcare crises.
Strategic Implications for the NHS and UK Healthcare
The timing of this move couldn’t be more strategic. The NHS is facing unprecedented pressure with record waiting lists exceeding 7 million patients and growing demand for elective procedures. Narayana’s acquisition positions them as a solution provider to the very crisis the NHS has been struggling to manage. What’s particularly clever about targeting Practice Plus Group is that it gives Narayana immediate scale and NHS contracts without the regulatory hurdles of building from scratch. In my analysis, we’re likely to see Narayana apply its famous “assembly line” approach to common procedures like joint replacements and cataract surgeries, potentially reducing costs by 30-40% while maintaining quality through standardized protocols.
The Caribbean Connection and Global Ambitions
Shetty’s expansion pattern reveals a carefully calibrated global strategy. The Cayman Islands hospital, established in 2014, served as the perfect testing ground for Western regulatory standards and medical protocols while maintaining proximity to the U.S. market. That facility’s success with medical tourism and complex procedures provided the confidence to tackle a mature market like the UK. What we’re witnessing is the emergence of a new breed of healthcare multinational—one that originates from emerging markets but competes effectively in developed ones. The next logical expansion targets would likely be Canada and Australia, where similar public healthcare systems face cost and access challenges.
Long-Term Industry Disruption Trajectory
This acquisition signals a fundamental shift in global healthcare dynamics that I believe will accelerate over the next 24 months. Traditional Western healthcare providers have focused on premium pricing and technological innovation, while emerging market players like Narayana have mastered operational efficiency and scale. The convergence of these models could create hybrid systems that deliver both quality and accessibility. We’re likely to see increased M&A activity as other Indian healthcare giants like Apollo and Fortis explore similar international expansions. The bigger question is whether Western providers will begin adopting Narayana’s cost-efficient methodologies in response. This could trigger a wave of operational restructuring across the global healthcare industry as the pressure to deliver more with less becomes universal.
Investment and Regulatory Considerations
From an investment perspective, this move represents a calculated bet on healthcare system reform. The UK’s increasing reliance on private providers to manage NHS backlogs creates a favorable environment for operators who can demonstrate both cost efficiency and quality outcomes. However, the regulatory landscape presents significant challenges. Narayana will need to navigate the UK’s Care Quality Commission standards, medical staffing regulations, and political sensitivities around NHS privatization. The company’s experience operating within India’s complex regulatory environment may prove valuable, but cultural adaptation will be crucial. Success in the UK could position Narayana as the template for future healthcare delivery in aging Western populations where cost containment becomes increasingly critical.
